OTC •
Healthcare •
Biotechnology •
Quote as of 05/19/2026 15:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization1.21 mln
Float35.14 mln
Piotroski F-Score
2
/ 9
Weak
Relative Strength
14
/ 100
Significantly lagging
Debt / Equity
-0.13
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
Business Description
CERo Therapeutics Holdings Inc. is a California-based biotech company working to develop new cancer treatments using specially modified immune cells. Founded in 2021 and headquartered in South San Francisco, the company is currently focused on its primary drug candidate, CER-1236, which is designed to treat both blood cancers and solid tumors. This treatment uses a patient's own T cells, which are collected, engineered, and returned to the body to fight cancer more effectively.
